The CE approval may open new doors but I doubt it
Post# of 7795
(Total Views: 391)
Posted On: 05/25/2020 12:59:30 PM
Re: graveldrive #2449
The CE approval may open new doors but I doubt it affects our current negotiations. The shift to OEM Supplier should reduce BIEL's regulatory responsibilities.
* in discussion with a global player in the orthopedic devices industry that specializes in products for rehabilitation, pain therapy, physical therapy, and surgical reconstructive implants. Our intended relationship is as an OEM supplier where, the partner would use ActiPatch technology to differentiate their line of products in the marketplace. They will contribute significant assets for promotional activities of the product, including a direct-sales team of several hundred. The initial contract proposal is for the North American territory and is expected to generate more than $2 million in sales for BioElectronics, in 2020.
* Mundipharma expansion in Middle East/North Africa region
* discussions with two large corporations who have demonstrated an interest to distribute the product in South Africa and Russia
* One of our channel partners has finalized a deal with an American multinational health care services company to place ActiPatch in 1000 independently owned stores and launch under an initiative for alternative pain therapies
* If Dr Scholl's is one of the prospective partners their territory covers only North America/Latin America
* If KT-Tape is one of the prospective partners our roll as an OEM supplier most likely means they would need to get their own CE approval for their device in the EU Market
* in discussion with a global player in the orthopedic devices industry that specializes in products for rehabilitation, pain therapy, physical therapy, and surgical reconstructive implants. Our intended relationship is as an OEM supplier where, the partner would use ActiPatch technology to differentiate their line of products in the marketplace. They will contribute significant assets for promotional activities of the product, including a direct-sales team of several hundred. The initial contract proposal is for the North American territory and is expected to generate more than $2 million in sales for BioElectronics, in 2020.
* Mundipharma expansion in Middle East/North Africa region
* discussions with two large corporations who have demonstrated an interest to distribute the product in South Africa and Russia
* One of our channel partners has finalized a deal with an American multinational health care services company to place ActiPatch in 1000 independently owned stores and launch under an initiative for alternative pain therapies
* If Dr Scholl's is one of the prospective partners their territory covers only North America/Latin America
* If KT-Tape is one of the prospective partners our roll as an OEM supplier most likely means they would need to get their own CE approval for their device in the EU Market
(0)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼